TG makes case for umbralisib as safer lymphoma option

Bolstering support for what could be the third PI3Kδ inhibitor to gain FDA approval, TG Therapeutics said umbralisib met the primary endpoint in a second lymphoma indication in the Phase IIb UNITY-NHL trial.

TG Therapeutics Inc. (NASDAQ:TGTX)

Read the full 362 word article

User Sign In